Transgene (LTS:0OCQ) Valuation Rank


LTS:0OCQ Transgene SA LTS:0OCQ
49 GF Score
Price €0.73
GF Value €0.52
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Transgene Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Transgene Valuation Rank Related Terms

LTS:0OCQ
49GF Score
Transgene SA LTS:0OCQ
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Transgene (LTS:0OCQ) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene stock appears to be overvalued. The current stock price of €0.73 is trading 41.2% above its estimated GF Value™ of €0.52. GuruFocus considers Transgene to be Significantly Overvalued.

Key valuation signals for LTS:0OCQ:

  • Valuation Rank:
  • GF Value™: €0.52 vs. price of €0.73 (41.2% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the LTS:0OCQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Business Description

Address 400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
49GF Score

Get the complete analysis for LTS:0OCQ

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.73
Price
€0.52
GF Value